Publications by authors named "L Rigacci"
: Retrospective studies are often criticized for their susceptibility to case selection bias compared to prospective studies, which include all patients consecutively and are thus less prone to such limitations. However, the larger sample sizes typical of retrospective studies can sometimes offset this drawback. On behalf of the Fondazione Italiana Linfomi (FIL), a substantial retrospective study involving 946 patients was conducted to examine the use of non-pegylated liposomal anthracycline (Myocet).
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess trabecular attenuation of the L1 vertebral body using low-dose CT in adult patients with multiple myeloma (MM), smoldering myeloma (SMM), and monoclonal gammopathy of undetermined significance (MGUS).
- The study included 73 patients, with evaluations of trabecular bone density based on CT scans, showing significant differences in bone density among the different patient groups.
- Results indicated that lower Hounsfield unit (HU) values are associated with poorer progression-free survival, highlighting the potential clinical relevance of L1 attenuation values in managing these conditions.
Article Synopsis
- The IELSG37 trial investigated whether patients with primary mediastinal B-cell lymphoma (PMBCL) who have a complete metabolic response (CMR) after treatment can safely skip consolidation radiotherapy.
- It was a randomized noninferiority study involving 545 patients, focusing on progression-free survival (PFS) over 30 months, with results showing high PFS rates of 96.2% for observation and 98.5% for radiotherapy.
- The study concluded that avoiding irradiation does not negatively impact survival, highlighting positive outcomes for patients with CMR.
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL). Despite the availability of clinical and molecular algorithms applied for the prediction of prognosis, in up to 30%-40% of patients, intrinsic or acquired drug resistance occurs. Constitutional genetics may help to predict R-CHOP resistance.
View Article and Find Full Text PDFArticle Synopsis
- Bullous pemphigoid (BP) is a rare blistering skin disease that may signal underlying cancers, particularly hematological malignancies like acute myeloid leukemia (AML).
- A 28-year-old male patient with both BP and de novo AML was treated using a combination of immunosuppressive therapy and chemotherapy to effectively address both conditions.
- After aggressive treatment, the patient achieved full remission from AML and complete resolution of BP, along with normalized BP180 antibody levels after receiving an autologous stem cell transplant.